Nitric oxide-releasing drugs

被引：185

作者：

Napoli, C ^{[1
]}

Ignarro, LJ

机构：

[1] Univ Calif San Diego, Dept Med 0682, La Jolla, CA 92093 USA

[2] Univ Naples Federico II, Dept Med, I-80131 Naples, Italy

[3] Univ Calif Los Angeles, Hlth Sci Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2003年 / 43卷

关键词：

beta-blockers; NO-aspirin; ACE-inhibitors; cardiovascular disease; S-nitrosothiols; nitroprusside;

D O I：

10.1146/annurev.pharmtox.43.100901.140226

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacological compounds that release nitric oxide (NO) have been useful tools for evaluating the broad role of NO in physiology and therapeutics. NO deficiency has been implicated in the genesis and evolution of several disease states. Both medical needs and commercial opportunities have fostered attempts to modulate NO in the human body for therapeutic gain. Strategies for NO modulation encompass antiinflammatory, sexual dysfunction, and cardiovascular indications. Apart from newly developed drugs, several commonly used cardiovascular drugs exert their beneficial action, at least in part, by modulating the NO pathway. This review discusses the fundamental pharmacological properties and mechanisms of action of NO-releasing drugs. Some of these compounds may enter in the clinical arena providing important therapeutic benefits in human diseases.

引用

页码：97 / 123

页数：27

共 151 条

[41] Effect of L-arginine administration on myocardial thallium-201 perfusion during exercise in patients with angina pectoris and normal coronary angiograms [J].

Fujita, H ;

Yamabe, H ;

Yokoyama, M .

JOURNAL OF NUCLEAR CARDIOLOGY, 2000, 7 (02) :97-102

[42] NEBIVOLOL INDUCES ENDOTHELIUM-DEPENDENT RELAXATIONS OF CANINE CORONARY-ARTERIES [J].

GAO, YS ;

NAGAO, T ;

BOND, RA ;

JANSSENS, WJ ;

VANHOUTTE, PM .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 (06) :964-969

[43]

*GISSI PREV INV, 2000, LANCET, V354, P447

[44]

GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181

[45] Role of nitric oxide [J].

Gupta, TK ;

Toruner, M ;

Groszmann, RJ .

DIGESTION, 1998, 59 (04) :413-415

[46] Gastric toxicity of antiplatelet therapy with low-dose aspirin [J].

Guslandi, M .

DRUGS, 1997, 53 (01) :1-5

[47] Inhaled nitric oxide in cardiology [J].

Hayward, CS ;

Macdonald, PS ;

Keogh, AM .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (11) :1947-1956

[48] Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells [J].

Hernández-Perera, O ;

Pérez-Sala, D ;

Navarro-Antolín, J ;

Sánchez-Pascuala, R ;

Hernández, G ;

Díaz, C ;

Lamas, S .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (12) :2711-2719

[49] Nitric oxide as a signaling molecule in the vascular system: An overview [J].

Ignarro, LJ ;

Cirino, G ;

Casini, A ;

Napoli, C .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1999, 34 (06) :879-886

[50] Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide - An overview [J].

Ignarro, LJ ;

Napoli, C ;

Loscalzo, J .

CIRCULATION RESEARCH, 2002, 90 (01) :21-28

← 1 2 3 4 5 6 7 8 9 10 →